Rebecca Fortescue

Rebecca Fortescue

Auto-generated profile, based on publicly available information

Rebecca Fortescue

Population Health Research Institute, St George's, University of London, London, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2021 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
SJSadia Janjua
Sadia Janjua
PPPippa Powell
Pippa Powell
RARichard Atkinson
Richard Atkinson
ESElizabeth Stovold
Elizabeth Stovold
RFRebecca Fortescue
Rebecca Fortescue
Background More than 90% of the global population lives in areas exceeding World Health Organization air quality limits. More than four million people each year are thought to die early due to air pollution, and poor air quality is thought to reduce an average European's life expectancy by one year. Individuals may be able to reduce health risks through interventions such as masks, behavioural changes and use of air quality alerts. To date, evidence is lacking about the efficacy and safety of such interventions for the general population and people with long‐term respiratory conditions. This topic, and the review question relating to supporting evidence to avoid or lessen the effects of air pollution, emerged directly from a group of people with chronic obstructive pulmonary disease (COPD) in South London, UK. Objectives 1. To assess the efficacy, safety and acceptability of individual‐level interventions that aim to help people with or without chronic respiratory conditions to reduce their exposure to outdoor air pollution. 2. To assess the efficacy, safety and acceptability of individual‐level interventions that aim to help people with chronic respiratory conditions reduce the personal impact of outdoor air pollution and improve health outcomes. Search methods We identified studies from the Cochrane Airways Trials Register, Cochrane Central Register of Controlled Trials, and other major databases. We did not restrict our searches by date, language or publication type and included a search of the grey literature (e.g. unpublished information). We conducted the most recent search on 16 October 2020. Selection criteria We included randomised controlled trials (RCTs) and non‐randomised studies (NRS) that included a comparison treatment arm, in adults and children that investigated the effectiveness of an individual‐level intervention to reduce risks of outdoor air pollution. We included studies in healthy individuals and those in people with long‐term respiratory conditions. We excluded studies which focused on non‐respiratory long‐term conditions, such as cardiovascular disease. We did not restrict eligibility of studies based on outcomes. Data collection and analysis We used standard Cochrane methods. Two review authors independently selected trials for inclusion, extracted study characteristics and outcome data, and assessed risk of bias using the Cochrane Risk of Bias tool for RCTs and the Risk Of Bias In Non‐randomised Studies ‐ of Interventions (ROBINS‐I) as appropriate. One review author entered data into the review; this was spot‐checked by a second author. We planned to meta‐analyse results from RCTs and NRS separately, using a random‐effects model. This was not possible, so we presented evidence narratively. We assessed certainty of the evidence using the GRADE approach. Primary outcomes were: measures of air pollution exposure; exacerbation of respiratory conditions; hospital admissions; quality of life; and serious adverse events. Main results We identified 11 studies (3372 participants) meeting our inclusion criteria (10 RCTs and one NRS). Participants’ ages ranged from 18 to 74 years, and the duration of studies ranged from 24 hours to 104 weeks. Six cross‐over studies recruited healthy adults and five parallel studies included either people with pre‐existing conditions (three studies) or only pregnant women (two studies). Interventions included masks (e.g. an N95 mask designed to filter out airborne particles) (five studies), an alternative cycle route (one study), air quality alerts and education (five studies). Studies were set in Australia, China, Iran, the UK, and the USA. Due to the diversity of study designs, populations, interventions and outcomes, we did not perform any meta‐analyses and instead summarised results narratively. We judged both RCTs and the NRS to be at risk of bias from lack of blinding and lack of clarity regarding selection methods. Many studies did not provide a prepublished protocol or trial registration. From five studies (184 participants), we found that masks or altered cycle routes may have little or no impact on physiological markers of air pollution exposure (e.g. blood pressure and heart rate variability), but we are very uncertain about this estimate using the GRADE approach. We found conflicting evidence regarding health care usage from three studies of air pollution alerts, with one non‐randomised cross‐over trial (35 participants) reporting an increase in emergency hospital attendances and admissions, but the other two randomised parallel trials (1553 participants) reporting little to no difference. We also gave the evidence for this outcome a very uncertain GRADE rating. None of our included trials reported respiratory exacerbations, quality of life or serious adverse events. Secondary outcomes were not well reported, but indicated inconsistent impacts of air quality alerts and education interventions on adherence, with some trials reporting improvements in the intervention groups and others reporting little or no difference. Symptoms were reported by three trials, with one randomised cross‐over trial (15 participants) reporting a small increase in breathing difficulties associated with the mask intervention, one non‐randomised cross‐over trial (35 participants) reporting reduced throat and nasal irritation in the lower‐pollution cycle route group (but no clear difference in other respiratory symptoms), and another randomised parallel trial (519 participants) reporting no clear difference in symptoms between those who received a smog warning and those who did not. Authors' conclusions The lack of evidence and study diversity has limited the conclusions of this review. Using a mask or a lower‐pollution cycle route may mitigate some of the physiological impacts from air pollution, but...

1 June 2018 in Health Technology Assessment
Verified
Journal Article
Closed access
THTess Harris
Tess Harris
SKSally Kerry
Sally Kerry
CVChristina R Victor
Christina R Victor
SIStephen Iliffe
Stephen Iliffe
MUMichael Ussher
Michael Ussher
DCDerek Cook
Derek Cook
Background: Guidelines recommend walking to increase moderate to vigorous physical activity (MVPA) for health benefits.Objectives: To assess the effectiveness, cost-effectiveness and acceptability of a pedometer-based walking intervention in inactive adults, delivered postally or through dedicated practice nurse physical activity (PA) consultations.Design: Parallel three-arm trial, cluster randomised by household.Setting: Seven London-based general practices.Participants: A total of 11,015 people without PA contraindications, aged 45–75 years, randomly selected from practices, were invited. A total of 6399 people were non-responders, and 548 people self-reporting achieving PA guidelines were excluded. A total of 1023 people from 922 households were randomised to usual care (n = 338), postal intervention (n = 339) or nurse support (n = 346). The recruitment rate was 10% (1023/10,467). A total of 956 participants (93%) provided outcome data.Interventions: Intervention groups received pedometers, 12-week walking programmes advising participants to gradually add ‘3000 steps in 30 minutes’ most days weekly and PA diaries. The nurse group was offered three dedicated PA consultations.Main outcome measures: The primary and main secondary outcomes were changes from baseline to 12 months in average daily step counts and time in MVPA (in ≥ 10-minute bouts), respectively, from 7-day accelerometry. Individual resource-use data informed the within-trial economic evaluation and the Markov model for simulating long-term cost-effectiveness. Qualitative evaluations assessed nurse and participant views. A 3-year follow-up was conducted.Results: Baseline average daily step count was 7479 [standard deviation (SD) 2671], average minutes per week in MVPA bouts was 94 minutes (SD 102 minutes) for those randomised. PA increased significantly at 12 months in both intervention groups compared with the control group, with no difference between interventions; additional steps per day were 642 steps [95% confidence interval (CI) 329 to 955 steps] for the postal group and 677 steps (95% CI 365 to 989 steps) for nurse support, and additional MVPA in bouts (minutes per week) was 33 minutes per week (95% CI 17 to 49 minutes per week) for the postal group and 35 minutes per week (95% CI 19 to 51 minutes per week) for nurse support. Intervention groups showed no increase in adverse events. Incremental cost per step was 19p and £3.61 per minute in a ≥ 10-minute MVPA bout for nurse support, whereas the postal group took more steps and cost less than the control group. The postal group had a 50% chance of being cost-effective at a £20,000 per quality-adjusted life-year (QALY) threshold within 1 year and had both lower costs [–£11M (95% CI –£12M to –£10M) per 100,000 population] and more QALYs [759 QALYs gained (95% CI 400 to 1247 QALYs)] than the nurse support and control groups in the long term. Participants and nurses found the interventions acceptable and enjoyable. Three-year follow-up data showed persistent intervention effects (nurse support plus postal vs. control) on steps per day [648 steps (95% CI 272 to 1024 steps)] and MVPA bouts [26 minutes per week (95% CI 8 to 44 minutes per week)].Limitations: The 10% recruitment level, with lower levels in Asian and socioeconomically deprived participants, limits the generalisability of the findings. Assessors were unmasked to the group.Conclusions: A primary care pedometer-based walking intervention in 45- to 75-year-olds increased 12-month step counts by around one-tenth, and time in MVPA bouts by around one-third, with similar effects for the nurse support and postal groups, and persistent 3-year effects. The postal intervention provides cost-effective, long-term quality-of-life benefits. A primary care pedometer intervention delivered by post could help address the public health physical inactivity challenge.Future work: Exploring different recruitment strategies to increase uptake. Integrating the Pedometer And Consultation Evaluation-UP (PACE-UP) trial with evolving PA monitoring technologies.Trial registration: Current Controlled Trials ISRCTN98538934.Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 22, No. 37. See the NIHR Journals Library website for further project information.

1 September 2022 in Breathe
Verified
Journal Article
Open access
PDF file
Anne B. ChangAnne B. Chang
Anne B. Chang
JBJeanette Boyd
Jeanette Boyd
ABAndrew Bush
Andrew Bush
AHAdam T. Hill
Adam T. Hill
ZPZena Powell
Zena Powell
KGKeith Grimwood
Keith Grimwood
The global burden of bronchiectasis in children and adolescents is being recognised increasingly. However, marked inequity exists between, and within, settings and countries for resources and standards of care afforded to children and adolescents with bronchiectasis compared with those with other chronic lung diseases. The European Respiratory Society (ERS) clinical practice guideline for the management of bronchiectasis in children and adolescents was published recently. Here we present an international consensus of quality standards of care for children and adolescents with bronchiectasis based upon this guideline.The panel used a standardised approach that included a Delphi process with 201 respondents from the parents and patients’ survey, and 299 physicians (across 54 countries) who care for children and adolescents with bronchiectasis.The seven quality standards of care statements developed by the panel address the current absence of quality standards for clinical care related to paediatric bronchiectasis. These internationally derived, clinician-, parent- and patient-informed, consensus-based quality standards statements can be used by parents and patients to access and advocate for quality care for their children and themselves, respectively. They can also be used by healthcare professionals to advocate for their patients, and by health services as a monitoring tool, to help optimise health outcomes.

1 November 2019 in The Lancet
Verified
Journal Article
Open access
CWCharlotte Wahlich
Charlotte Wahlich
UCUmar A R Chaudhry
Umar A R Chaudhry
RFRebecca Fortescue
Rebecca Fortescue
DCDerek G Cook
Derek G Cook
SHShashi Hirani
Shashi Hirani
THTess Harris
Tess Harris

5 January 2026 in BJGP Open
Verified
Journal Article
Open access
PDF file
RBRichard Baskerville
Richard Baskerville
FRFiona Reid
Fiona Reid
POPippa Oakeshott
Pippa Oakeshott
RFRebecca Fortescue
Rebecca Fortescue
Background: Cardiovascular disease (CVD) is the main cause of mortality in type 2 diabetes mellitus (T2DM) and detection of CVD risk is a key part of routine care. Slow walking speed is strongly correlated with CVD events in the general population. Aim: To see whether there is an association between reduced walking speed and increased CVD incidence in people with T2DM. Design & setting: Systematic review of studies of people with T2DM. Method: We searched studies in which usual walking speed was recorded, and participants were followed up for subsequent fatal and non-fatal cardiovascular events. PubMed Central, Web of Science, Cochrane Central Register of Controlled Trials, and Google Scholar were searched in December 2024. Studies were screened by two independent reviewers. Studies reporting walking speed or comparable indices and CVD outcomes in T2DM were included. Study quality was assessed using the Newcastle–Ottawa Scale. Heterogeneity of study populations prevented meta-analysis. Results: Out of 1281 studies identified, 53 full texts were retrieved and four were included, which were all of good quality. These involved 132 967 individuals with diabetes from the USA, the UK, and Japan. Mean study follow-up was 3–14 years. All four studies assessed walking speed by self-reported questionnaire and reported significant associations between reduced walking speed and increased CVD risk with risk or hazard ratios ranging from 1.18–5.88 ( P <0.001–0.0001). Conclusion: This is the first systematic review to indicate an association between reduced walking speed and increased CVD incidence in T2DM. This association is seen across diverse populations and settings. Further research in T2DM could explore whether increasing walking speed reduces CVD risk.